Cradle Bio vs Schrödinger
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cradle provides an AI platform for protein engineering that accelerates the design of improved enzymes, antibodies, and other biologics for industrial and therapeutic use.
About
Cradle Bio is an AI protein engineering company founded in 2021 in Amsterdam, having raised $73M to build an AI-powered protein design platform. The platform combines generative AI with wet-lab experimentation to accelerate the iterative process of engineering proteins with improved stability, activity, and manufacturability. Cradle's technology enables researchers to design thousands of protein variants computationally and prioritize those most likely to succeed in laboratory validation, compressing protein engineering timelines from years to months. The company serves both industrial biotechnology customers engineering enzymes for biomanufacturing and pharmaceutical companies developing next-generation antibody therapeutics. Cradle partners with contract research organizations and biopharmaceutical companies to integrate AI-assisted protein design into existing discovery workflows. The company has been recognized as a leader in the European deep tech ecosystem and positions protein engineering AI as enabling a new era of designed biologics for medicine and sustainable manufacturing.
Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in early 2025.
About
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has developed the industry-leading molecular modeling suite used by academic researchers, biotech startups, and large pharmaceutical companies to predict molecular properties, optimize lead compounds, and design drugs with greater precision than traditional empirical approaches.\n\nSchrödinger's platform—spanning FEP+ (free energy perturbation), Glide docking, WaterMap, and machine learning-enhanced property prediction—is used by over 1,700 organizations across pharma, biotech, and materials science. In early 2025, the company signed a landmark $150 million upfront collaboration with Novartis for multi-target drug discovery with potential milestones exceeding $2.3 billion. Software revenue grew 54% year-over-year in Q3 2025 as pharmaceutical companies accelerated adoption of computational-first drug discovery. Schrödinger also operates a proprietary drug pipeline, with SGR-1505 (MALT1 inhibitor) in Phase 1 for B-cell malignancies.\n\nSchrödinger occupies a unique hybrid position—part software platform, part drug discovery company—and is a benchmark of the AI/physics-based drug discovery movement. The company is publicly traded (SDGR) and is recognized as an essential tool for the modern small-molecule drug discovery workflow.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.